Can Evecxia Therapeutics turn EVX-101 into the first serotonin synthesis amplification therapy?
EVX-101 revives serotonin synthesis as an SSRI add-on strategy. Can Evecxia prove old biology still has new clinical value?
Pharma & Biotech
Pharma & Biotech
ReST Therapeutics wins FDA IND acceptance for RST-101 as early PTSD treatment strategy enters human testing
ReST Therapeutics’ RST-101 enters human testing for early PTSD. Find out why this IND acceptance could reshape trauma care.
Pharma & Biotech
Alzamend Neuro moves AL001 into bipolar disorder patients as lithium reformulation race intensifies
Alzamend Neuro, the Nasdaq-listed clinical-stage biopharmaceutical company, has initiated a Phase II clinical trial of AL001, its ionic cocrystal lithium formulation, in patients diagnosed with bipolar disorder type 1, conducting the study at Massachusetts General Hospital in collaboration with Harvard Medical School investigators. The trial employs a crossover design in which participants receive both AL001
Pharma & Biotech
What Evecxia’s EVX-301 trial reveals about the future of serotonin-based psychiatry
Evecxia’s Phase 1b study uses direct brain biomarkers to validate serotonin synthesis amplification. Find out why this matters for antidepressant development.